Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$103.55M+2730.24%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Derek J. Maetzold
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 1,002
- Beta
- 1.00
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 7.68
Financials
Revenue
$103.55M+2730.2%Net Income
$-2.06MEBITDA
$2.57MFree Cash Flow
$6.55MEPS (diluted)
$-0.07Shares Outstanding (diluted)
30.40M+185.4%Operating Expenses
$80.67MCash & Debt
$266.81MRevenue by Segment (annual)
$216.37MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $344.23M | $-24.16M | $-0.83 |
| 2024 | $332.07M | $18.25M | $0.66 |
| 2023 | $219.79M | $-57.47M | $-2.14 |
| 2022 | $137.04M | $-67.14M | $-2.58 |
| 2021 | $94.08M | $-31.29M | $-1.24 |
| 2020 | $62.65M | $-10.28M | $-0.54 |
| 2019 | $51.87M | $5.28M | $0.35 |
| 2018 | $22.79M | $-6.37M | $-0.60 |
| 2017 | $13.75M | $-12.37M | $-1.26 |
Valuation
CSTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
75-37.50%Social Signal Score
Mentions (8)
- Newsprnewswire.com·5d ago·Negative
…n in stage IIB disease, supporting closer surveillance when staging is uncertain FRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereology (EADV) Congress 2026, taking place Sept.
View source ↗ - Newsprnewswire.com·8d ago·Neutral
…Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE).
View source ↗ - Newsprnewswire.com·11d ago·Positive
…ressed interest in molecular testing to help identify a more effective treatment FRIENDSWOOD, Texas, Sept. 24, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selection.
View source ↗ - Newsprnewswire.com·14d ago·Positive
Castle Biosciences to Open New Laboratory Facility in Scottsdale New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of its new laboratory and office facility in Scottsdale, Arizona.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
…result identified patients most likely to benefit from adjuvant radiation therapy FRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of Dermatology (JAAD) validating the integrated DecisionDx-SCC test result (i40-GEP) for patients with high-risk cutaneous squamous cell carcinoma (SCC).1 …
View source ↗ - Newszacks.com·38d ago·Neutral
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
Castle Biosciences to Participate in Upcoming Investor Conferences FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m.
View source ↗ - Newsmarketbeat.com·54d ago·Positive
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction Castle Biosciences NASDAQ: CSTL reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-0.38 per share
Typical surprise +82.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$-0.07 vs $-0.41beat
- Wed, May 6$-0.49 vs $-0.49beat
- Thu, Feb 26$-0.08 vs $-0.23beat
- Mon, Nov 3$-0.02 vs $-0.34beat
- Mon, Aug 4$0.15 vs $-0.51beat
- Mon, May 5$-0.90 vs $-0.08miss
Estimates and results for CSTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CSTL officers and directors.
- Bought
- —
- Sold
- $8.2m
0 trades
76 trades
- Juvenal Tobin Wsold
- Juvenal Tobin Wsold
- Maetzold Derek Jsold
- Maetzold Derek Jsold
- Maetzold Derek Jsold
- Juvenal Tobin Wsold
- Juvenal Tobin Wsold
- Maetzold Derek Jsold
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 17, 2022 (33d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (17d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.